Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products worldwide. It operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The company also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is based in Salisbury South, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-8-82092666
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$561.43 million
Profitability
Miscellaneous
Employees780
Next Earnings DateN/A
OptionableNot Optionable
Mayne Pharma Group (ASX:MYX) Frequently Asked Questions
What is Mayne Pharma Group's stock symbol?
Mayne Pharma Group trades on the ASX under the ticker symbol "MYX."
Has Mayne Pharma Group been receiving favorable news coverage?
News articles about MYX stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mayne Pharma Group earned a news impact score of 1.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are some of Mayne Pharma Group's key competitors?
Some companies that are related to Mayne Pharma Group include Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS), Futura Medical (FUM), Cathay International (CTI), Recce Pharmaceuticals (RCE) and Patrys (PAB).
What other stocks do shareholders of Mayne Pharma Group own?
Who are Mayne Pharma Group's key executives?
Mayne Pharma Group's management team includes the folowing people:
- Mr. Scott Anthony Richards, MD, CEO & Exec. Director (Age 55)
- Mr. Nick Freeman BCom, CA, Group CFO & Company Sec.
- Mr. Stefan J. Cross, Pres of International Operations (Age 46)
- Dr. Ilana Stancovski, Chief Scientific Officer & Head of European Market Devel.
- Ms. Lisa Pendlebury, VP of Investor Relations & Communications
What is Mayne Pharma Group's stock price today?
One share of MYX stock can currently be purchased for approximately A$0.59.
How big of a company is Mayne Pharma Group?
Mayne Pharma Group has a market capitalization of $926.02 million and generates $561.43 million in revenue each year. Mayne Pharma Group employs 780 workers across the globe.
What is Mayne Pharma Group's official website?
How can I contact Mayne Pharma Group?
Mayne Pharma Group's mailing address is 1538 Main North Rd, ADELAIDE, SA 5106, Australia. The company can be reached via phone at +61-8-82092666.
MarketBeat Community Rating for Mayne Pharma Group (ASX MYX)
MarketBeat's community ratings are surveys of what our community members think about Mayne Pharma Group and other stocks. Vote "Outperform" if you believe MYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
